Journal of Chinese Pharmaceutical Sciences ›› 2016, Vol. 25 ›› Issue (1): 3-11.DOI: 10.5246/jcps.2016.01.001

• Review • Previous Articles     Next Articles

Effect of Rho-ROCK signaling pathway on pulmonary fibrosis

Wenying Yu1, Chenhuan Yu1, Wei Dai2, Jieyin Sun1*   

  1. 1. Institute of Materia Medica, Zhejiang Academy of Medical Sciences, Hangzhou 310013, China
    2. Hangzhou Dongxiang Pharmaceutical Technology Co., Ltd., Hangzhou 310000, China
  • Received:2015-10-09 Revised:2015-11-04 Online:2016-01-27 Published:2015-11-10
  • Contact: Tel.: 0571-88215628, E-mail:
  • About author:Wenying Yu graduated from Zhejiang Chinese Medical University in 2008 and obtained her Master degree, majoring in pharmacy. After graduation, she was working in the Institute of Materia Medica, Zhejiang Academy of Medical Sciences. At present, she is in charge of Natural Science Foundation of Zhejiang Province, Administration of Traditional Chinese Medicine of Zhejiang Province and other research projects. As the technical backbone, she has developed at least 2 types of second grade national new medicine and obtained two national patents granted by China’s Patent Office. Her research interests include: (1) New drug targets discovery and targeted drug development; (2) Research and development of targeted drug delivery and controlled release drug delivery.
  • Supported by:

    Zhejiang Provincial Natural Science Foundation of China (Grant No. LQ15H280007), National Natural Science Foundation of China (Grant No. 81202977), project of Traditional Chinese Medicine Science of Zhejiang province (Grant No. 2013ZA026 and 2016ZA042).


Idiopathic pulmonary fibrosis (IPF) is characterized by progressive lung scarring, reduced median survival, poor prognosis and limited therapeutic options, leading to great need for new pharmacologic therapies. In recent years, researchers have found that Rho-ROCK signaling pathway may be a new drug target in the prevention of IPF. This article reviewed the role of Rho-ROCK pathway in pulmonary fibrosis and the application of ROCK inhibitors in experimental models of IPF. Multiple lines of evidence therefore indicated that ROCK inhibition has great potential to be a powerful therapeutic tool in the prevention and treatment of IPF in clinic. 

Key words: Rho-ROCK signaling pathway, Pulmonary fibrosis, Inhibitor, Drug targets

CLC Number: